Gene editing of the beta-globin gene to treat sickle cell disease may be complicated by co-editing at the closely related delta globin gene. Cutting by nucleases (like CRISPR or zinc finger nucleases) at both beta- and delta-globin can lead to chromosomal rearrangements. These types of complications need to be assessed in pre-clinical studies to enure patient safety.